# A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

> **NCT02154425** · PHASE1 · COMPLETED · sponsor: **UCB BIOSCIENCES, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Axial Spondyloarthritis (AxSpA)
- Non-radiographic Evidence-AxSpA
- Ankylosing Spondylitis
- Crohn's Disease
- Psoriatic Arthritis
- Rheumatoid Arthritis

## Interventions

- **PROCEDURE:** Breast milk sampling
- **BIOLOGICAL:** Certolizumab Pegol

## Key facts

- **NCT ID:** NCT02154425
- **Lead sponsor:** UCB BIOSCIENCES, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-12
- **Final completion:** 2016-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2018-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02154425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02154425, "A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02154425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*